Human interleukin-2

Generic Name: Human interleukin-2

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: FNO32LO217

Background: Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

Phase 1

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Hydroxychloroquine
Drug: IL-2

First Posted Date: 2012-03-12

Last Posted Date: 2020-01-02

Lead Sponsor: Leonard Appleman

Target Recruit Count: 30

Registration Number: NCT01550367

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, United States
🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Loyola University Chicago, Maywood, Illinois, United States

and more 4 locations

Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation

Not Applicable

Terminated

Conditions: Leukemia

Interventions: Drug: Interleukin-2

First Posted Date: 2012-01-25

Last Posted Date: 2016-10-24

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 90

Registration Number: NCT01517347

Locations: 🇨🇳
Xiaosu Zhao, Beijing, Beijing, China

A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2

Phase 2

Completed

Conditions: Malignant Melanoma

Interventions: Drug: Interleukin-2
Drug: Ipilimumab

First Posted Date: 2011-11-28

Last Posted Date: 2015-07-21

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 15

Registration Number: NCT01480323

Locations: 🇩🇪
University Hospital Tübingen, Tübingen, Germany

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Drug: Temozolomide
Drug: Cisplatin
Drug: Interferon Alfa-2b
Drug: Interleukin-2

First Posted Date: 2011-08-04

Last Posted Date: 2017-05-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT01409174

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia
Leukemia

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Interleukin-2
Drug: Anti-Thymocyte Globulin
Procedure: Allogeneic related Stem Cell Transplant
Drug: Tacrolimus
Drug: Methotrexate
Drug: G-CSF

First Posted Date: 2011-07-11

Last Posted Date: 2016-02-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01390402

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions: Drug: Preparative Regimen
Biological: NK Cells
Drug: Interleukin-2
Biological: CD34 Graft/Anti-thymocyte globulin
Biological: Donor TCR α/β-depleted Graft/ATG

First Posted Date: 2011-06-09

Last Posted Date: 2020-05-13

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 25

Registration Number: NCT01370213

Locations: 🇺🇸
University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 1 locations

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Phase 2

Active, not recruiting

Conditions: Chronic Graft-versus-host Disease

Interventions: Drug: Interleukin-2

First Posted Date: 2011-06-03

Last Posted Date: 2024-01-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 35

Registration Number: NCT01366092

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

Phase 2

Terminated

Conditions: Acute Myelogenous Leukemia

Interventions: Drug: Interleukin-2

First Posted Date: 2011-02-04

Last Posted Date: 2019-09-12

Lead Sponsor: Leo W. Jenkins Cancer Center

Target Recruit Count: 18

Registration Number: NCT01289678

Locations: 🇺🇸
Leo W. Jenkins Cancer Center, Greenville, North Carolina, United States

IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

Completed

Conditions: Malignant Melanoma

Interventions: Drug: IL-2

First Posted Date: 2011-02-03

Last Posted Date: 2023-06-15

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 153

Registration Number: NCT01288963

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

Phase 2

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Bevacizumab
Drug: Interleukin-2
Drug: Interferon Alfa-2b

First Posted Date: 2011-01-11

Last Posted Date: 2014-12-02

Lead Sponsor: University of Aarhus

Target Recruit Count: 118

Registration Number: NCT01274273

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰
Herlev University Hospital, Herlev, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy